文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

骨肉瘤的免疫抑制性肿瘤微环境

Immunosuppressive Tumor Microenvironment of Osteosarcoma.

作者信息

Taylor Aaron Michael, Sheng Jianting, Ng Patrick Kwok Shing, Harder Jeffrey M, Kumar Parveen, Ahn Ju Young, Cao Yuliang, Dzis Alissa M, Jillette Nathaniel L, Goodspeed Andrew, Bodlak Avery, Wu Qian, Isakoff Michael S, George Joshy, Grassmann Jessica D S, Luo Diane, Flynn William F, Courtois Elise T, Robson Paul, Hayashi Masanori, Paolillo Alini Trujillo, Petrilli Antonio Sergio, Caminada de Toledo Silvia Regina, Balarezo Fabiola Sara, Lindsay Adam D, Hoang Bang, Wong Stephen T C, Lau Ching C

机构信息

The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.

Systems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston, TX 77030, USA.

出版信息

Cancers (Basel). 2025 Jun 24;17(13):2117. doi: 10.3390/cancers17132117.


DOI:10.3390/cancers17132117
PMID:40647416
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12248827/
Abstract

Osteosarcoma is the most common malignant bone tumor in children, characterized by a high degree of genomic instability, resulting in copy number alterations and genomic rearrangements without disease-defining recurrent mutations. Clinical trials based on molecular characterization have failed to find new effective therapies or improve outcomes over the last 40 years. To better understand the immune microenvironment of osteosarcoma, we performed single-cell RNA sequencing on six tumor biopsy samples, combined with a previously published cohort of six samples. Additional osteosarcoma samples were profiled using spatial transcriptomics for the validation of discovered subtypes and to add spatial context. Analysis revealed immunosuppressive cells, including myeloid-derived suppressor cells (MDSCs), regulatory and exhausted T cells, and LAMP3+ dendritic cells. Using cell-cell communication modeling, we identified robust interactions between MDSCs and other cells, leading to NF-κB upregulation and an immunosuppressive microenvironment, as well as interactions involving regulatory T cells and osteosarcoma cells that promoted tumor progression and a proangiogenic niche.

摘要

骨肉瘤是儿童最常见的恶性骨肿瘤,其特征是高度的基因组不稳定,导致拷贝数改变和基因组重排,而无明确疾病的复发性突变。在过去40年中,基于分子特征的临床试验未能找到新的有效疗法或改善治疗结果。为了更好地了解骨肉瘤的免疫微环境,我们对6个肿瘤活检样本进行了单细胞RNA测序,并结合了之前发表的6个样本队列。使用空间转录组学对额外的骨肉瘤样本进行分析,以验证发现的亚型并增加空间背景信息。分析揭示了免疫抑制细胞,包括髓源性抑制细胞(MDSC)、调节性T细胞和耗竭性T细胞,以及LAMP3+树突状细胞。通过细胞间通讯建模,我们确定了MDSC与其他细胞之间的强烈相互作用,导致NF-κB上调和免疫抑制微环境,以及涉及调节性T细胞和骨肉瘤细胞的相互作用,这些相互作用促进了肿瘤进展和促血管生成微环境。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b13c/12248827/470524d05cb5/cancers-17-02117-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b13c/12248827/9f39829a389b/cancers-17-02117-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b13c/12248827/508ce17e86b4/cancers-17-02117-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b13c/12248827/b76b1b9aebae/cancers-17-02117-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b13c/12248827/e061e96bc6f9/cancers-17-02117-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b13c/12248827/fafba92cf4c9/cancers-17-02117-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b13c/12248827/470524d05cb5/cancers-17-02117-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b13c/12248827/9f39829a389b/cancers-17-02117-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b13c/12248827/508ce17e86b4/cancers-17-02117-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b13c/12248827/b76b1b9aebae/cancers-17-02117-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b13c/12248827/e061e96bc6f9/cancers-17-02117-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b13c/12248827/fafba92cf4c9/cancers-17-02117-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b13c/12248827/470524d05cb5/cancers-17-02117-g006.jpg

相似文献

[1]
Immunosuppressive Tumor Microenvironment of Osteosarcoma.

Cancers (Basel). 2025-6-24

[2]
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.

Clin Orthop Relat Res. 2025-1-1

[3]
Does Augmenting Irradiated Autografts With Free Vascularized Fibula Graft in Patients With Bone Loss From a Malignant Tumor Achieve Union, Function, and Complication Rate Comparably to Patients Without Bone Loss and Augmentation When Reconstructing Intercalary Resections in the Lower Extremity?

Clin Orthop Relat Res. 2025-6-26

[4]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2017-12-22

[5]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

[6]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2021-4-19

[7]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2020-1-9

[8]
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.

Health Technol Assess. 2001

[9]
Interventions for interpersonal communication about end of life care between health practitioners and affected people.

Cochrane Database Syst Rev. 2022-7-8

[10]
Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review.

JBI Database System Rev Implement Rep. 2017-8

本文引用的文献

[1]
A single-cell and spatially resolved atlas of human osteosarcomas.

J Hematol Oncol. 2024-8-20

[2]
The whole transcriptome analysis using FFPE and fresh tissue samples identifies the molecular fingerprint of osteosarcoma.

Exp Biol Med (Maywood). 2024

[3]
Single-cell transcriptional profiling in osteosarcoma and the effect of neoadjuvant chemotherapy on the tumor microenvironment.

J Bone Oncol. 2024-5-8

[4]
Single-cell and spatial transcriptomics reveal metastasis mechanism and microenvironment remodeling of lymph node in osteosarcoma.

BMC Med. 2024-5-17

[5]
Interleukin-1 receptor antagonist: An alternative therapy for cancer treatment.

Life Sci. 2023-12-15

[6]
Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment.

Bone Res. 2023-2-27

[7]
Role of tumor microenvironment in cancer progression and therapeutic strategy.

Cancer Med. 2023-5

[8]
Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation.

Nat Commun. 2023-1-3

[9]
Characterizing the tumor microenvironment at the single-cell level reveals a novel immune evasion mechanism in osteosarcoma.

Bone Res. 2023-1-3

[10]
EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer.

Sci Adv. 2022-12-16

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索